Latest news with #CancerVaccines
Telegraph
7 days ago
- Health
- Telegraph
Cancer vaccines to be given to patients with deadly head and neck tumours
Cancer vaccines will be given to NHS patients with deadly head and neck tumours. A trial of jabs that could cure people's cancer and prevent it from returning is being expanded to include more than 100 patients with mouth, throat and other head-related cancers, over the next year. The world-first programme has already been trialling personalised cancer vaccines in some 550 patients with either bowel or skin cancers. Tens of thousands of patients will be recruited to trial the various vaccines in development for different forms of the disease over the coming years. The programme, called the NHS Cancer Vaccine Launch Pad, uses a 'match-making' service to partner eligible cancer patients with appropriate trials at nearby hospitals, led by the Southampton Clinical Trials Unit. The cancer vaccines use 'mRNA' technology, first pioneered to create Covid-19 jabs during the pandemic. The vaccine used in this trial, known as AHEAD-MERIT (BNT113-01), will help the immune system recognise and kill cancer cells containing human papillomavirus (HPV) proteins, which are commonly linked to head and neck cancers. Around 11,000 new cases of head and neck cancer are diagnosed in England every year, with a recent University of Sheffield study finding rates had increased by 47 per cent between 2013 and 2020. Aggressive forms of the disease are difficult to treat and have high rates of returning, while fewer than 50 per cent of patients will live for two years after being diagnosed. The vaccine used in the trial is encoded with two proteins that are commonly found in head and neck cancers associated with high-risk types of HPV. It trains the body's immune system to attack and kill the cancer cells. Prof Peter Johnson, NHS England's national clinical director for cancer, said it was a 'potentially transformative vaccine, offering renewed hope of holding the disease at bay'. 'The NHS is always looking for evidence-backed innovations in treatment to improve survival and quality of life for people diagnosed with cancer, and this expansion of our Cancer Vaccine Launch Pad will give hundreds of patients the chance to be part of cutting-edge advances in cancer care,' he said. It will be available to selected patients from 15 NHS hospitals over the next 12 months, NHS England said, which is partnering with German life sciences company BioNTech on the programme. The announcement to expand trials into vaccines using mRNA technology comes after Robert F Kennedy Jr, the US health secretary, announced he would cancel $500 million in funding for mRNA vaccines to tackle viruses that cause diseases such as flu and Covid-19. Kennedy, a vaccine sceptic, said he was pulling the funding over claims that 'mRNA technology poses more risks than benefits for these respiratory viruses', in a move that has been heavily criticised. Karin Smyth MP, the health minister, said the new cancer vaccine trial was a 'massive win' for Britain and 'could be game-changing for patients facing some of the most challenging diagnoses'. 'By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation,' she said. Lord Vallance, the science minister and former chief scientific officer for the Government, said: 'Our partnership with BioNTech is delivering for patients right across the country, and I hope to see more ambitious work like this as they continue to invest in research and development and AI as part of their billion-pound backing for the UK over the next 10 years.' Chris Curtis, 67, from Blackpool, was diagnosed with a HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. He said: 'When I was diagnosed with stage four tongue cancer and two secondary cancers, one each side of the neck, my world just fell apart. 'I then had to go through brutal treatment, including six weeks of radiotherapy, chemotherapy every week, two neck dissections and be fed on a tube for almost three years. I lost 12 stone in weight and was severely physically and mentally unwell. 'With this aggressive cancer you live in fear every day – so anything that could help control the disease or give people peace of mind is ground-breaking. 'It'll allow people to get on with their lives and move forward.' Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said the launch pad was an 'important route to fast-track promising mRNA vaccine technology into clinical trials'. 'Research into personalised cancer treatments is vital. 'There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone.'
Globe and Mail
07-08-2025
- Business
- Globe and Mail
Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon
The Key Cancer Vaccines Companies in the market include - Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others. DelveInsight's 'Cancer Vaccines Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cancer Vaccines, historical and forecasted epidemiology as well as the Cancer Vaccines market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Cancer Vaccines Market Report: The Cancer Vaccines market size is anticipated to grow with a significant CAGR during the study period (2020-2034) In March 2025, Everest Medicines administered the first dose of EVM16, its personalized mRNA cancer vaccine, to a participant in the first-in-human (FIH) trial, EVM16CX01. In February 2025, In a Phase I investigator-led trial, all nine patients who received a personalized kidney cancer vaccine developed anti-cancer immune responses after undergoing tumor removal surgery. Researchers at the Dana-Farber Cancer Institute in the U.S. administered the NeoVax personalized cancer vaccine to patients with stage III or IV clear cell renal cell carcinoma (ccRCC) following their surgeries. In August 2024, BioNTech launched global clinical trials for BNT116, an mRNA vaccine being developed as a potential treatment for non-small cell lung cancer (NSCLC). The vaccine utilizes the same mRNA technology that played a crucial role in the development of Covid-19 vaccines. In February 2024, A cancer vaccine trial initiated by Moderna commenced in the UK, with researchers optimistic about ushering in a new era of treatments. In 2023, the estimated number of incident cases of non-small cell lung cancer (NSCLC) in the US was approximately 200,000. Uveal melanoma impacts approximately 500 to 600 individuals annually in the UK. The cancer vaccines market features a robust and expanding pipeline with candidates such as IO102-IO103 (IO Biotech), CAN-2409 (Candel Therapeutics), mRNA-4157 (V940) combined with KEYTRUDA (Merck and Moderna), PDClung01 (PDCline Pharma/LG Chem), and LB-LR1109 (LG Chem and AVEO Oncology). These vaccines target a variety of cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, glioblastoma, melanoma, breast cancer, and more. Key Cancer Vaccines Companies: Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others Key Cancer Vaccines Therapies: DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others Several vaccine constructions have been tested for anticancer therapy. In each case, these vaccines are designed to present tumor-associated peptides integrated with MHC molecules to cognate receptors on B or T lymphocytes and stimulate their activation, maturation, and proliferation The Cancer Vaccines market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Vaccines pipeline products will significantly revolutionize the Cancer Vaccines market dynamics. Cancer Vaccines Overview Cancer vaccines are a type of immunotherapy designed to stimulate the body's immune system to recognize and attack cancer cells. Unlike traditional vaccines, which prevent infectious diseases by priming the immune system to recognize and fight off specific pathogens (such as viruses or bacteria), cancer vaccines are used to treat existing cancer or to prevent cancer recurrence. Cancer Vaccines Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Cancer Vaccines Epidemiology Segmentation: The Cancer Vaccines market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Cancer Vaccines Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Vaccines market or expected to get launched during the study period. The analysis covers Cancer Vaccines market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Cancer Vaccines Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Cancer Vaccines Therapies and Key Companies Cancer Vaccines Market Strengths Advancements in computational and bioinformatics platforms and several other R&D practices enable the development of cancer neoantigen vaccination strategies Neoantigen-based Personalized Cancer Therapeutic Vaccines like Vigil and Tedopi along with few others can stimulate immune responses to checkpoint inhibitors even in patients that have previously failed conventional treatment regimes, thereby, addressing potential unmet needs of the market Cancer Vaccines Market Opportunities Rising incidence of cancer will provide a larger window of opportunity for these novel vaccines Recurrence is very common in cancers even after proper treatment. This opens up new window for Neoantigen-based Personalized Cancer Therapeutic Vaccines to dominate the treatment regime Scope of the Cancer Vaccines Market Report Table of Contents 1. Cancer Vaccines Market Report Introduction 2. Executive Summary for Cancer Vaccines 3. SWOT analysis of Cancer Vaccines 4. Cancer Vaccines Patient Share (%) Overview at a Glance 5. Cancer Vaccines Market Overview at a Glance 6. Cancer Vaccines Disease Background and Overview 7. Cancer Vaccines Epidemiology and Patient Population 8. Country-Specific Patient Population of Cancer Vaccines 9. Cancer Vaccines Current Treatment and Medical Practices 10. Cancer Vaccines Unmet Needs 11. Cancer Vaccines Emerging Therapies 12. Cancer Vaccines Market Outlook 13. Country-Wise Cancer Vaccines Market Analysis (2020–2034) 14. Cancer Vaccines Market Access and Reimbursement of Therapies 15. Cancer Vaccines Market Drivers 16. Cancer Vaccines Market Barriers 17. Cancer Vaccines Appendix 18. Cancer Vaccines Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
